|Assessment Status||Rapid Review Complete|
|Drug||Niraparib in combination with abiraterone acetate|
|Indication||Niraparib in combination with abiraterone acetate and prednisone/prednisolone is indicated for the treatment of adults with metastatic castration resistant prostate cancer (mCRPC) and BRCA1/2 mutations (germline and/or somatic) in whom chemotherapy is not clinically indicated.|
|Rapid review commissioned||06/06/2023|
|Rapid review completed||11/07/2023|
|Rapid review outcome||A full HTA is not recommended. The NCPE recommends that niraparib in combination with abiraterone acetate not be considered for reimbursement at the submitted price*.|
*This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.